Global Price Controls Cost Rx Industry $18-$27 Bil. A Year, Commerce Says
Executive Summary
Global price controls cost pharmaceutical companies approximately $18 bil. to $27 bil. a year in lost revenue, the Commerce Department maintains in a Dec. 21 report to Congress entitled "Foreign Drug Price Controls: Their Effects on R&D, Innovation and Consumer Welfare.
You may also be interested in...
High Prices For Biologics Abroad Serve Political Purpose In U.S. – AEI Report
The high price of biologics in overseas markets could be the result of manufacturers' political considerations in the U.S., the authors of an American Enterprise Institute/Brookings Institution working paper suggest
High Prices For Biologics Abroad Serve Political Purpose In U.S. – AEI Report
The high price of biologics in overseas markets could be the result of manufacturers' political considerations in the U.S., the authors of an American Enterprise Institute/Brookings Institution working paper suggest
Free Trade Agreements Not Useful Against Price Controls – Commerce Official
The Commerce Department does not view free trade agreements as an effective tool to change international pharmaceutical price controls